A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled, parallel-arm study will evaluate the
safety and exploratory efficacy and pharmacokinetics of RO4917523 in pediatric patients with
fragile X syndrome. Patients will be randomized to receive one of 2 dose levels of RO4917523
or placebo orally daily for 12 weeks.